Giant Biogene Holding Co., Ltd. has scheduled its 2025 annual general meeting for 28 May 2026 at 1:30 p.m. in Xi’an, Shaanxi Province. The proxy circular lists seven ordinary resolutions for shareholder approval:
• FY 2025 Financials Shareholders will receive and consider the audited consolidated financial statements, directors’ report and auditor’s report for the year ended 31 December 2025.
• Board Composition Re-election of executive directors Ms. Fang Juan, Ms. Zhang Huijuan and Ms. Yan Yubo is proposed, together with authorisation for the board to set their remuneration.
• Auditor Rotation KPMG is nominated as independent auditor following the retirement of Ernst & Young, with authority for the board to determine its remuneration.
• Share Repurchase Mandate Directors seek a new mandate to buy back up to 10% of the company’s issued shares (excluding treasury shares) as at the date of the resolution.
• Issuance Mandate A separate mandate would allow directors to allot and issue additional shares up to 20% of issued share capital (excluding treasury shares). A further resolution extends this limit by adding any shares repurchased under the buy-back mandate.
• Dividend Distribution The board proposes a final dividend of RMB0.5390 per share and a special dividend of RMB0.6714 per share for FY 2025, totalling RMB1.2104 per share.
Proxy forms must reach Tricor Investor Services Limited in Hong Kong no later than 1:30 p.m. on 26 May 2026. Completion of a proxy form does not preclude a shareholder from attending and voting in person at the AGM.
Comments